| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.28 | 0.0002 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.13 | 0.005 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.006 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.008 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.073 | 0.01 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.01 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | -0.28 | 0.01 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.12 | 0.01 |